5. Remodeling the Tumor Microenvironment to Bolster ICB Immune Therapy—Lessons from CDK4/6-MEK Inhibition in Other Ras-Driven Cancers Guiding Efforts in MPNSTs. Here, MAP2K7 is linked to neoplasm.